BioAge Labs raises $90 million as they look to continue developing medicines to treat age-related diseases
BioAge Labs, Inc., whose co-founder and CEO is Kristen Fortney, raises a large round as it works to develop medicines to treat aging and aging-related diseases. The Richmond, Calif. company raised $90 million in Series C financing from Andreessen Horowitz, Elad Gill, Kaiser Foundation Hospitals, AARP Foundation, Phi-X Capital, Redpoint Ventures, Pear VC, AME Cloud Ventures and Felicis Ventures. The company is seeking to develop a broad pipeline of therapies that target aging in order to increase health span and address chronic diseases. In a statement, Kristen said BioAge will use the capital to support advancement of its biology and data-driven platform “to map the key pathways that drive human aging and our pipeline of medicines that target these pathways to reverse or eradicate diseases and extend health span.” The company, she said, will be advancing its first platform-derived therapies into clinical trials in the first half of 2021. Kristen, who has a deep background in aging research and systems biology, founded BioAge in 2015 with Dr. Eric Morgen, who is COO. https://bioagelabs.com/.